ALMIB Amoéba S.A.
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.…
Industry Peers
Agricultural InputsKey Statistics
About Amoéba (EPA: ALMIB)
›
Amoéba (EPA: ALMIB) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Agricultural Inputs industry, part of the Basic Materials sector, and reports about 23 employees.
The shares were at 0.2595 EUR on 20 November 2026, down 71.7% over 52 weeks. Its 52-week range is 0.2475 EUR to 1.120 EUR: the price is 76.8% below the high and 4.8% above the low.
Its market capitalisation is 33.58M EUR.
Amoéba reports return on equity of 154.9% and revenue up 66.3% year over year.
Its debt exceeds its cash by 7.14M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 1.000 EUR is 285.4% above the current price.